Daiichi Sankyo completes trio of major edoxaban filings
This article was originally published in Scrip
Following a submission for the novel anticoagulant in the EU earlier this week, and in Japan in December, Daiichi Sankyo has filed an NDA for the US approval of edoxaban in what will be its main commercial indications.
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.